FindTrial
Sign In

Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer

The changing pattern of positron emission tomography scan derived parameters in prediction of response after neoadjuvant chemotherapy for borderline resectable and locally advanced pancreatic cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0009052
Enrollment
200
Registered
2023-12-15
Start date
2021-01-01
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Asan Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Compatible with borderline resectable or locally advanced pancreatic cancer based on NCCN - Administered neoadjuvant chemotherapy before surgery - Available data of positive emission tomographym and carbohydrate antigen 19-9 during neoadjuvant chemotherapy

Exclusion criteria

Exclusion criteria: - The patients with distant metastasis - The patients who underwent upfront surgery without neoadjuvant chemotherapy

Design outcomes

Primary

MeasureTime frame
overall survival—

Secondary

MeasureTime frame
recurrence free survival—

Countries

Korea, Republic of

Contacts

Public ContactSong Cheol Kim

Asan Medical Center

drksc@amc.seoul.kr+82-2-3010-3936

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026